Exelixis Inc. (NASDAQ:EXEL) went down by -0.20% from its latest closing price compared to the recent 1-year high of $27.80. The company’s stock price has collected 3.08% of gains in the last five trading sessions. Press Release reported on 09/21/20 that Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab
Is It Worth Investing in Exelixis Inc. (NASDAQ :EXEL) Right Now?
Exelixis Inc. (NASDAQ:EXEL) scored a price-to-earnings ratio above its average ratio, recording 27.44 x from its present earnings ratio. Plus, the 36-month beta value for EXEL is at 1.29. Opinions of the stock are interesting as 10 analysts out of 15 who provided ratings for Exelixis Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $31.46, which is $7.01 above the current price. EXEL currently public float of 298.82M and currently shorts hold a 3.31% ratio of that float. Today, the average trading volume of EXEL was 2.13M shares.
EXEL’s Market Performance
EXEL stocks went up by 3.08% for the week, with a monthly jump of 10.04% and a quarterly performance of 4.04%, while its annual performance rate touched 37.82%. The volatility ratio for the week stands at 3.67% while the volatility levels for the past 30 days are set at 4.61% for Exelixis Inc.. The simple moving average for the period of the last 20 days is 4.03% for EXEL stocks with a simple moving average of 14.19% for the last 200 days.
Analysts’ Opinion of EXEL
Many brokerage firms have already submitted their reports for EXEL stocks, with Barclays repeating the rating for EXEL by listing it as a “Overweight.” The predicted price for EXEL in the upcoming period, according to Barclays is $26 based on the research report published on March 04th of the current year 2020.
SunTrust, on the other hand, stated in their research note that they expect to see EXEL reach a price target of $31. The rating they have provided for EXEL stocks is “Buy” according to the report published on January 13th, 2020.
BofA/Merrill gave a rating of “Buy” to EXEL, setting the target price at $22 in the report published on November 13th of the previous year.
EXEL Trading at 5.68% from the 50-Day Moving Average
After a stumble in the market that brought EXEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.05% of loss for the given period.
Volatility was left at 4.61%, however, over the last 30 days, the volatility rate increased by 3.67%, as shares surge +13.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.37% lower at present.
During the last 5 trading sessions, EXEL rose by +3.08%, which changed the moving average for the period of 200-days by +37.21% in comparison to the 20-day moving average, which settled at $23.65. In addition, Exelixis Inc. saw 38.76% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at EXEL starting from Hessekiel Jeffrey, who sale 10,258 shares at the price of $26.14 back on Sep 22. After this action, Hessekiel Jeffrey now owns 343,026 shares of Exelixis Inc., valued at $268,144 using the latest closing price.
Haley Patrick J., the EVP, Commercial of Exelixis Inc., sale 4,680 shares at $26.09 during a trade that took place back on Sep 21, which means that Haley Patrick J. is holding 115,571 shares at $122,101 based on the most recent closing price.
Stock Fundamentals for EXEL
Current profitability levels for the company are sitting at:
- +38.18 for the present operating margin
- +96.58 for the gross margin
The net margin for Exelixis Inc. stands at +33.17. The total capital return value is set at 24.31, while invested capital returns managed to touch 21.16. Equity return is now at value 16.40, with 14.70 for asset returns.
Based on Exelixis Inc. (EXEL), the company’s capital structure generated 3.01 points at debt to equity in total, while total debt to capital is 2.92. Total debt to assets is 2.68, with long-term debt to equity ratio resting at 2.85. Finally, the long-term debt to capital ratio is 2.76.
Currently, EBITDA for the company is 78.94M with total debt to EBITDA at 0.00. When we switch over and look at the enterprise to sales, we see a ratio of 4.71, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 6.47 and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.08.